Company News
- Home
- News & Events
- Company News
-
2023 Summer Internship Program: BiOptic x Chang Gung Department of Biomedical Sciences
2023-09-02Throughout this season, six interns became part of the BiOptic team, collaborating closely with our Research and Development, Marketing, and Department teams. Their growth during the internship was remarkable, and they infused our team with fresh ideas and boundless energy.
-
Zhejiang BiOptic has received Class I medical device certification
2023-04-27BiOptic registered its’ second-tier subsidiary Zhejiang BiOptic on NOV 23rd, 2021, and has received Class I medical device certification. In the future, for the overall production and manufacturing capacity of BiOptic Group, it will be possible to have more diverse plans and increase productivity to effectively match the needs of the global market.
-
BiOptic has received ISO13485 certification from TÜV Rheinland - BiOptic
2023-02-24BiOptic has received ISO13485 certification from TÜV Rheinland, which will be a strong asset for us to explore the international market. Relevant primary quality certification includes ISO 9001, ISO 13485, and EU CE.
-
【Congratulations!】BiOptic has received an US patent
2023-01-03【Congratulations!】We have received a patent from USPTO for the multi-channel cartridge of the Qsep400 bio-fragment analyzer!
-
Congratulations! BiOptic has won“The 25th Rising Star Award”
2022-11-17BiOptic has won“The 25th Rising Star Award”, which is awarded by the Ministry of Economic Affairs. We are so honored that BiOptic could stands out from all Bio-industry companies in Taiwan and be the only Bio-company of the 16 winning companies from various industries. The award ceremony was held on the 16th of November, and Dr. Ming-Jhy Hsu, Chief R&D Director, representing BiOptic to receive this award.
-
BiOptic hits a new high in revenue in the first 10-month of 2022
2022-11-11The world's largest medical tradeshow, MEDICA, in Dusseldorf Germany will be held from November 14th to 17th. BiOptic will participate in the exhibition for the first time after the COVID-19 epidemic. Chairman Eric Tsai said that the company has actively expanded the European market in recent years and the penetration rate continues to increase.